Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01640522 · ClinicalTrials.gov registry record · NA

Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms

A NA study of Pancreatic Cancer and Hepatocellular Carcinoma, sponsored by University of Pittsburgh.

Completed
Registry status
NA
Development phase
261
Enrollment target
1
Study location

NCT01640522 is a NA study of Pancreatic Cancer and Hepatocellular Carcinoma that has completed, run by University of Pittsburgh. The registered enrollment target is 261 participants, below the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01640522, a NA study of Pancreatic Cancer and Hepatocellular Carcinoma, has completed, sponsored by University of Pittsburgh.

COMPLETED
Registry status
NA
Development phase
261 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test the efficacy of a collaborative care intervention to manage cancer-related symptoms and improve health related quality of life in patients diagnosed with hepatobiliary carcinoma.

Interventions

  • OTHER Collaborative Care
  • OTHER Enhanced usual Care

Study Locations (1)

Pennsylvania

  • University of Pittsburgh Medical Center - Pittsburgh

Trial Details

FieldValue
Enrollment Target 261 participants
Start Date 2008-01
Est. Completion 2014-12
Phase NA

Sponsor

University of Pittsburgh

1,238 total trials

What the Registry Record Tells You About NCT01640522

The ClinicalTrials.gov registry entry for NCT01640522 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 261 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (33% lower). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Collaborative Care is the first listed.

NCT01640522 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01640522 about?

NCT01640522 is a clinical study titled "Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms". The purpose of this study is to test the efficacy of a collaborative care intervention to manage cancer-related symptoms and improve health related quality of life in patients diagnosed with hepatobiliary carcinoma.

What is the current status of trial NCT01640522?

This trial is currently completed. It is a NA study. The enrollment target is 261 participants. The study started on 2008-01. Estimated completion is 2014-12.

What conditions does trial NCT01640522 study?

This clinical trial studies the following conditions: Pancreatic Cancer, Hepatocellular Carcinoma, Colorectal Carcinoma, Liver Metastases, Bile Duct Cancer.

What interventions are being tested in trial NCT01640522?

The interventions under investigation include: Collaborative Care (OTHER), Enhanced usual Care (OTHER).

Who is sponsoring clinical trial NCT01640522?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01640522 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.